Physician profile
Chris Boggs
NPI 1326068362
$3,408.49
in general payments reported to CMS, 2019-2025
28 companies · $809 in 2025
The $809 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,104 · 2020: $304 · 2022: $134 · 2023: $539 · 2024: $518 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,834 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,834.18 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $686.33 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $389.96 | 2019-2025 | Ozempic, Rybelsus, Esperoct |
| Lilly USA, LLC | $339.05 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $289.78 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $203.16 | 2019-2025 | |
| Boston Scientific Corporation | $183.17 | 2024-2025 | Watchman Flx |
| Amarin Pharma, INC. | $178.52 | 2019-2020 | |
| Amgen INC. | $169.31 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $146.88 | 2022-2025 | |
| Astellas Pharma US INC | $110.30 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $96.78 | 2019-2020 | |
| Abbott Laboratories | $94.95 | 2023-2025 | Freestyle Libre 3, Freestyle Libre |
| Xeris Pharmaceuticals, INC. | $92.23 | 2023-2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $88.34 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $56.18 | 2024-2025 | Gemtesa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $44.96 | 2020-2023 | Eliquis |
| Phathom Pharmaceuticals, INC. | $32.69 | 2024-2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $27.53 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $25.21 | 2019 | |
| Scilex Pharmaceuticals INC. | $24.94 | 2023 | Ztlido |
| Axsome Therapeutics, INC. | $22.89 | 2025 | Symbravo |
| Irhythm Technologies, INC. | $18.84 | 2023 | Zio Xt Patch |
| Hologic Sales and Service, LLC | $16.37 | 2022 | |
| Dexcom, INC. | $15.95 | 2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.61 | 2023 | Xifaxan, Trulance |
| Mannkind Corporation | $14.62 | 2019 | |
| Aytu Biopharma, INC. | $12.90 | 2019 | |
| Zyla Life Sciences, INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Boggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.